Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beckwith, M
Right arrow Articles by Longo, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beckwith, M
Right arrow Articles by Longo, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Anti-IgM induces transforming growth factor-beta sensitivity in a human B-lymphoma cell line: inhibition of growth is associated with a downregulation of mutant p53

M Beckwith, FW Ruscetti, GK Sing, WJ Urba and DL Longo

Biological Carcinogenesis Development Program, Inc/DynCorp, National Cancer Institute, Frederick, MD 21702, USA.

We wished to examine the role of transforming growth factor-beta (TGF- beta) in the regulation of human lymphoma cell growth. The RL cell line is an immunoglobulin M (IgM)+, IgD+ B lymphoma cell line, which does not constitutively express receptors for TGF-beta, and thus has lost the ability to respond to the inhibitory effects of TGF-beta. We demonstrate here that anti-Ig antibodies can efficiently upregulate the expression of TGF-beta receptors and promote sensitivity to growth inhibition by TGF-beta. Furthermore, because TGF-beta has been shown to function in late G1 of the cell cycle, we examined the ability of TGF- beta to modulate two tumor suppressor proteins known to be critical regulators of the G1/S transition, Rb and p53. Rb is a 105- to 110-kD phosphoprotein, which has been shown to maintain its growth suppressive function when it is found in the hypophosphorylated state. Wild-type p53 is a 53-kD phosphoprotein that appears to be important in preventing cell-cycle progression and promoting apoptosis in cells with DNA damage, whereas mutant p53 can overcome those functions. We show here that TGF-beta treatment of phorbol myristate acetate (PMA) or anti- Ig-activated RL cells results in growth inhibition through a dual effect on Rb and mutant p53. After TGF-beta treatment, we observe a predominance of Rb in the hypophosphorylated, growth suppressive form. In addition, we show a decrease in levels of mRNA and protein for mutant p53. We also show that, although these changes are sufficient to halt progression through the cell cycle, the cells do not appear to undergo extensive programmed cell death following 72 hours of TGF-beta treatment. Thus, although these lymphoma cells maintain the capacity to be negatively growth regulated by TGF-beta, the ability of TGF-beta to induce apoptosis must be independently controlled.

Volume 85, Issue 9, pp. 2461-2470, 05/01/1995
Copyright © 1995 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
T. J. O'Farrell, P. Ghosh, N. Dobashi, C. Y. Sasaki, and D. L. Longo
Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression
Cancer Res., November 15, 2004; 64(22): 8199 - 8207.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. L. Szocinski, A. R. Khaled, J. Hixon, D. Halverson, S. Funakoshi, W. C. Fanslow, A. Boyd, D. D. Taub, S. K. Durum, C. B. Siegall, et al.
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax
Blood, June 17, 2002; 100(1): 217 - 223.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Husson, E. G. Carideo, D. Neuberg, J. Schultze, O. Munoz, P. W. Marks, J. W. Donovan, A. C. Chillemi, P. O'Connell, and A. S. Freedman
Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays
Blood, January 1, 2002; 99(1): 282 - 289.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. L. Ong, S. E. Elsamra, D. M. Goldenberg, and M. J. Mattes
Single-cell Cytotoxicity with Radiolabeled Antibodies
Clin. Cancer Res., January 1, 2001; 7(1): 192 - 201.
[Abstract] [Full Text]


Home page
J. Gen. Virol.Home page
G. J. Inman and M. J. Allday
Resistance to TGF-{beta}1 correlates with a reduction of TGF-{beta} type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines
J. Gen. Virol., June 1, 2000; 81(6): 1567 - 1578.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
T. L. Brown, S. Patil, C. D. Cianci, J. S. Morrow, and P. H. Howe
Transforming Growth Factor beta Induces Caspase 3-independent Cleavage of alpha II-Spectrin (alpha -Fodrin) Coincident with Apoptosis
J. Biol. Chem., August 13, 1999; 274(33): 23256 - 23262.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1995 by American Society of Hematology         Online ISSN: 1528-0020